Top Page
Zelira Therapeutics
(OTC:ZLD)
Zelira Therapeutics (ZLD) vs. iShares MSCI Australia ETF (EWA)
Zelira Therapeutics Business Overview & Revenue Model
Zelira Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 655.00 | 656.00 | 94.95K | 301.12K | 1.54M | 663.32K |
| Gross Profit | -802.95K | -802.95K | 10.28K | -3.22M | -5.72M | -39.16K |
| EBITDA | -4.17M | -4.17M | -36.44M | -6.79M | -13.06M | -9.41M |
| Net Income | -3.63M | -3.63M | -36.57M | -5.57M | -11.95M | -8.55M |
Balance Sheet | ||||||
| Total Assets | 1.30M | 1.30M | 5.18M | 33.89M | 37.70M | 39.37M |
| Cash, Cash Equivalents and Short-Term Investments | 5.66K | 5.66K | 586.16K | 146.21K | 2.75M | 4.97M |
| Total Debt | 2.14M | 2.14M | 5.95M | 437.90K | 500.91K | 551.08K |
| Total Liabilities | 5.59M | 5.59M | 9.36M | 2.18M | 2.01M | 1.54M |
| Stockholders Equity | -4.46M | -4.46M | -4.51M | 31.80M | 35.20M | 37.83M |
Cash Flow | ||||||
| Free Cash Flow | -4.91M | -4.91M | -4.39M | -7.25M | -9.43M | -8.62M |
| Operating Cash Flow | -4.91M | -4.91M | -4.39M | -7.25M | -9.43M | -8.62M |
| Investing Cash Flow | 1.15M | 1.15M | 919.74K | 2.83M | -207.78K | 1.38M |
| Financing Cash Flow | 3.19M | 3.19M | 3.92M | 1.77M | 7.10M | 10.53M |
Zelira Therapeutics Technical Analysis
Zelira Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | AU$9.77M | -20.63 | -8.72% | ― | ― | 71.10% | |
| ― | AU$44.90M | -10.71 | -16.65% | ― | ― | -672.73% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$14.28M | ― | -143.71% | ― | 306.88% | ― | |
| ― | AU$3.93M | ― | ― | ― | -99.31% | 90.20% | |
| ― | AU$6.62M | ― | -628.72% | ― | ― | 31.87% |
Zelira Therapeutics Corporate Events
Zelira Therapeutics has announced a non-dilutive R&D loan facility secured against its anticipated R&D tax incentive rebate for FY25, which will be used to advance the HOPE® SPV clinical trial and general working capital. Additionally, the company’s directors have provided unsecured loan notes to support operations. The company is making significant progress in its FDA program for the HOPE® clinical trial, with plans to launch Phase 1 trials for its HOPE® 1 Phelan McDermid Syndrome program. This development is part of Zelira’s strategy to bring effective cannabinoid-based therapies to market, targeting ultra-rare genetic conditions and improving patient outcomes.
The most recent analyst rating on (AU:ZLD) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
Zelira Therapeutics Limited announced the cessation of 125,723 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions and market positioning as the company continues its strategic initiatives.
The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
Zelira Therapeutics has announced its upcoming Annual General Meeting, scheduled for November 19, 2025, which will be held both virtually and physically in Perth. Key agenda items include the adoption of the remuneration report, re-election of director Greg Blake, and approval of convertible notes for Dr. Oludare Odumosu and Dr. Donna Gentile O’Donnell. Additionally, the company seeks to renew its proportional takeover provisions in the constitution. These resolutions, if passed, could impact the company’s governance and financial strategies, potentially influencing shareholder value and market perception.
The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
Zelira Therapeutics has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to ASX Corporate Governance Council’s principles, detailing the roles and responsibilities of the board and management, and the processes for director appointments and accountability, thereby reinforcing its commitment to transparency and effective governance practices.
The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
Zelira Therapeutics announced that its Managing Director, Dr. Oludare Odumosu, and Non-Executive Director, Dr. Donna Gentile O’Donnell, will provide a total of USD$150,000 in unsecured loan notes to the company. These funds will be used for general working capital purposes. The loan notes, subject to shareholder approval, may be converted into shares at a premium price, reflecting favorable terms for the company amidst current market conditions. This strategic financial move is expected to bolster Zelira’s operational capabilities and strengthen its market position.
The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
Zelira Therapeutics reported a significant increase in net loss for the year ended June 2025, despite making progress in clinical validation and development. The company has established a special purpose vehicle to conduct FDA trials for its HOPE® 1 product and has demonstrated the efficacy of its treatments in a study comparing them to Lyrica®. Zelira’s proprietary formulations under the HOPE® brand are generating revenue in multiple regions, and the company plans to expand its ZENIVOL® product into Germany. Additionally, Zelira is exploring commercialization opportunities for its Zyraydi™ technology and continues to generate revenue from its OTC products.
The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
Zelira Therapeutics has announced significant progress in its diabetic neuropathy study, with its proprietary cannabinoid-based therapy, ZLT-L-007, outperforming Lyrica® in reducing pain and improving quality of life for patients. This advancement, alongside the conversion of US$3.25 million in convertible notes into equity, strengthens Zelira’s financial position and supports its clinical and regulatory development efforts. The company is poised to continue its momentum with upcoming FDA trials and the optimization of its Zyraydi™ technology, aiming to unlock value across its product lines.